Literature DB >> 16211331

Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals".

Masoud H Manjili1, Hilal Arnouk, Keith L Knutson, Maciej Kmieciak, Mary L Disis, John R Subjeck, A Latif Kazim.   

Abstract

Breast tumors are shaped, in part, by a process termed immunoediting which selects for immunologically evasive phenotypes. In the present study we used the rat neu-transgenic mouse model of breast cancer and its congenic non-transgenic parental strain, FVB, to explore the phenotype of tumors that emerge in the presence of an immune response directed against the neu antigen. When inoculated into parental FVB mice, a neu-overexpressing mouse mammary carcinoma (MMC) cell line isolated from spontaneous breast tumors of the FVB neu (FVBN202) transgenic mouse, elicited a neu-specific immune response resulting in a tumor rejection because of the presence of the rat neu antigen. However, a neu negative variant (ANV) of MMC arose after a long latency in spite of the neu-specific immune response. We show that compared to MMC, ANV tumor cells have a significantly reduced ability to secrete pro-inflammatory cytokines and the CCL5 chemokine, to express immunostimulatory chaperones, and they have a distinct expression of proteins involved in cell motility, and metabolic and signal transduction pathways. These studies suggest that tumor escape through immunoediting can not be explained by the loss of a single tumor antigen, but rather by a selection process of a tumor variant that has a reduced ability to induce "danger signals" together with up-regulation of proteins involved in the tumor survival. Based on these findings, we propose to target novel antigens over-expressed in the escape variant of breast tumors to treat primary tumor and to prevent tumor relapse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16211331     DOI: 10.1007/s10549-005-9044-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.

Authors:  Maciej Kmieciak; Keith L Knutson; Catherine I Dumur; Masoud H Manjili
Journal:  Eur J Immunol       Date:  2007-03       Impact factor: 5.532

2.  Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Authors:  Andrea Worschech; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Aladar A Szalay; Ena Wang; Francesco M Marincola; Masoud H Manjili
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

3.  Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.

Authors:  Marta Santisteban; Jennifer M Reiman; Michael K Asiedu; Marshall D Behrens; Aziza Nassar; Kimberly R Kalli; Paul Haluska; James N Ingle; Lynn C Hartmann; Masoud H Manjili; Derek C Radisky; Soldano Ferrone; Keith L Knutson
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

4.  Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.

Authors:  Maciej Kmieciak; Johanna K Morales; Joshua Morales; Elizabeth Bolesta; Margaret Grimes; Masoud H Manjili
Journal:  Cancer Immunol Immunother       Date:  2008-02-16       Impact factor: 6.968

5.  Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.

Authors:  Mehran Habibi; Maciej Kmieciak; Laura Graham; Johanna K Morales; Harry D Bear; Masoud H Manjili
Journal:  Breast Cancer Res Treat       Date:  2008-04-20       Impact factor: 4.872

Review 6.  Tumor immunoediting and immunosculpting pathways to cancer progression.

Authors:  Jennifer M Reiman; Maciej Kmieciak; Masoud H Manjili; Keith L Knutson
Journal:  Semin Cancer Biol       Date:  2007-06-26       Impact factor: 15.707

7.  IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.

Authors:  Siqi Guo; Ronald B Smeltz; Anthony Nanajian; Richard Heller
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.